Entecavir as a first-line treatment for hepatitis B virus reactivation following polychemotherapy for chronic lymphocytic leukemia and invasive ductal carcinoma
| Autor: | Mustafa Cihat Oğan, Elçin Balc, Berna Oksuzoglu, Gülşen İskender, Murat Albayrak, Kamuran Turker, Fevzi Altuntaş |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Hepatitis B virus HBsAg Guanine Chronic lymphocytic leukemia Breast Neoplasms medicine.disease_cause Antiviral Agents Hepatitis B Chronic Recurrence Antineoplastic Combined Chemotherapy Protocols medicine Humans Hepatitis B Antibodies Hepatitis Hepatitis B Surface Antigens Hepatology business.industry Carcinoma Ductal Breast Gastroenterology virus diseases Lamivudine Entecavir Middle Aged Hepatitis B medicine.disease Hepatitis B Core Antigens Leukemia Lymphocytic Chronic B-Cell digestive system diseases Leukemia Immunology Female Virus Activation business medicine.drug |
| Zdroj: | European Journal of Gastroenterology & Hepatology. 27:39-45 |
| ISSN: | 0954-691X |
| Popis: | Objective Hepatitis B reactivation has been reported in chronic carriers of hepatitis B [hepatitis B surface antigen (HBsAg)] or in patients with prior hepatitis B virus (HBV) infection who are HBsAg-negative and have antibodies against hepatitis B core antigen (anti-HBc) with or without antibodies to HBsAg (anti-HBs). Lamivudine has been the first and commonly used nucleoside analog to inhibit HBV replication; however, prolonged therapy has been associated with an increased risk for drug-resistant mutations and mortality rates. Entecavir, a deoxyguanosine analog, offers several advantages over lamivudine for the treatment of HBV reactivation following chemotherapy while exhibiting more potent antiviral activity and a lower resistance rate. Methods Herein, we report rapid and sustained suppression of polychemotherapy-related HBV reactivation by entecavir administered as a prompt antiviral therapy in the cases of two patients with chronic lymphocytic leukemia and invasive ductal carcinoma. A review of the literature is discussed. Results Entecavir produced a rapid and sustained suppression of polychemotherapy-related HBV reactivation as a prompt antiviral therapy in the cases of two patients with chronic lymphocytic leukemia and invasive ductal carcinoma. Conclusion Allowing a rapid and sustained control of HBV replication, entecavir seems to be a promising drug for first-line prompt treatment of HBV reactivation in patients undergoing chemotherapy for hematological as well as solid organ malignancies, with safe long-term use enabling maintenance of resolved hepatitis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|